Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 105-112

  Ishii, Naoto ^a   Shirato, Manabu ^a   Wakita, Hisashi ^a   Miyazaki, Kazuki ^a   Takase, Yasutaka ^a   Asano, Osamu ^a   Kusano, Kazutomi ^a   Yamamoto, Eiichi ^a   Inoue, Chiharu ^a   Hishinuma, Ieharu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CILOMILAST; E 6005; FORSKOLIN; METHYL 4 [[[3 [6,7 DIMETHOXY 2 (METHYLAMINO)QUINAZOLIN 4 YL]PHENYL]AMINO]CARBONYL]BENZOATE; OXAZOLONE; PHOSPHODIESTERASE IV INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPRURITIC ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; IC 50; LYMPHOCYTE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPRURITICS; CELL ADHESION MOLECULES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LYMPHOCYTES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; MONOCYTES; PHOSPHODIESTERASE 4 INHIBITORS; PHTHALIC ACIDS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SKIN; TISSUE DISTRIBUTION;

EID: 84879324271     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205542     Document Type: Article

References (36)

1. Abrahamsen H, Baillie G, Ngai J., Vang T, Nika K, Ruppelt A., Mustelin T, Zaccolo M, Houslay M., and Taskén K (2004) TCR- and CD28-mediated recruitment of phos-phodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173:4847-4858.
2. Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H., Narumiya S, and Kuraishi Y (2007) Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J Invest Dermatol 127:2042-2047.
3. Andoh T, Saito A, and Kuraishi Y (2009) Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J Invest Dermatol 129:2854-2860.
4. Chan LS, Robinson N, and Xu L (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117:977-983.
5. Chen L, Lin SX, Amin S, Overbergh L., Maggiolino G, and Chan LS (2010) VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model. Immunol Cell Biol 88:334-342.
6. Chujor CS, Hammerschmid F, and Lam C (1998) Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epi-dermoid cell lines. J Invest Dermatol 110:287-291.
7. Draelos ZD (2008) Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin 24:985-994.
8. Gao XK, Nakamura N, Fuseda K., Tanaka H, Inagaki N, and Nagai H (2004) Establishment of allergic dermatitis in NC/Nga mice as a model for severe atopic dermatitis. Biol Pharm Bull 27:1376-1381.
9. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T., Langeveld-Wildschut AG, Ruzicka T, and Krutmann J (1998) A role for Th1 and Th2 cells in the immuno-pathogenesis of atopic dermatitis. Immunol Today 19:359-361.
10. Grewe SR, Chan SC, and Hanifin JM (1982) Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70:452-457.
11. Hanifin JM, Chan SC, Cheng J.B., Tofte SJ, Henderson WR, Jr, Kirby DS, and Weiner ES (1996) Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107:51-56.
12. Hashimoto Y, Arai I, Nakanishi Y., Sakurai T, Nakamura A, and Nakaike S (2004) Scratching of their skin by NC/Nga mice leads to development of dermatitis. Life Sci 76:783-794.
13. 1 T cells: a vicious circle of barrier disruption of the skin in atopic dermatitis. J Invest Dermatol 128 (S14):82.
14. Homey B, Steinhoff M, Ruzicka T., and Leung DY (2006) Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118:178-189.
15. Inagaki N, Igeta K, Kim J.F., Nagao M., Shiraishi N, Nakamura N, and Nagai H (2002) Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 448:175-183.
16. Jimenez JL, Punzón C, Navarro J., Muñoz-Fernández MA, and Fresno M (2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299:753-759.
17. Jin SL, Lan L, Zoudilova M., and Conti M (2005) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175: 1523-1531.
18. Leung DY, Boguniewicz M, Howell M.D., Nomura I., and Hamid QA (2004) New insights into atopic dermatitis. J Clin Invest 113:651-657.
19. Manning CD, Burman M, Christensen S.B., Cieslinski LB, Essayan DM, Grous M, Torphy T.J., and Barnette MS (1999) Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128:1393-1398.
20. Nambu A, Nakae S, and Iwakura Y (2006) IL-1beta, but not IL-1alpha, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses. Int Immunol 18:701-712.
21. Novak N and Bieber T (2003) Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 112:252-262.
22. Pagès L., Gavaldà A, and Lehner MD (2009) PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat 19:1501-1519.
23. Qian Y, Girard V, Martin CAE, Molimard M, and Advenier C (1994) Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 7:306-310.
24. Robichaud A, Savoie C, Stamatiou P.B., Tattersall FD, and Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharma-cology 40:262-269.
25. Robichaud A, Stamatiou PB, Jin S.L., Lachance N., MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, and Chan CC (2002) Deletion of phosphodiesterase 4D in mice shortens a(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:1045-1052.
26. Robichaud A, Tattersall FD, Choudhury I, and Rodger IW (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38:289-297.
27. Sawai T, Ikai K, and Uehara M (1995) Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis. Br J Dermatol 132:22-24.
28. Shichijo M, Inagaki N, Kimata M., Serizawa I, Saito H, and Nagai H (1999) Role of cyclic 39,59-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells. J Allergy Clin Immunol 103:S421-S428.
29. Shimada Y, Hasegawa M, Kaburagi Y., Hamaguchi Y, Komura K, Saito E., Takehara K, Steeber DA, Tedder T.F., and Sato S (2003) L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. J Immunol 170: 4325-4334.
30. Takano N, Arai I, Hashimoto Y., and Kurachi M (2004) Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. Eur J Pharmacol 495:159-165.
31. Tomimori Y, Tanaka Y, Goto M., and Fukuda Y (2005) Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition. J Invest Dermatol 124:119-124.
32. Torphy TJ, Zhou HL, and Cieslinski LB (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodies-terase activity. J Pharmacol Exp Ther 263:1195-1205.
33. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370.
34. Wahlgren CF (1999) Itch and atopic dermatitis: an overview. J Dermatol 26:770-779.
35. Webb EF, Tzimas MN, Newsholme S.J., and Griswold DE (1998) Intralesional cyto-kines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4. J Invest Dermatol 111:86-92.
36. Weishaar RE, Burrows SD, Kobylarz D.C., Quade MM, and Evans DB (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 35:787-800.